Daily Stock List
Lexam VG Gold, Inc. (LEXVF)
Today we are highlighting Lexam VG Gold, Inc. (LEXVF), here at the QualityStocks Daily Newsletter.
Lexam VG Gold, Inc. engages in acquiring, exploring, evaluating, and developing mineral properties. The Company is focusing on developing their four property assets from the heart of Canada's Timmins Gold Camp. This area is one of the most prolific gold producing regions of the world. The Timmins area is in northern Ontario; it has produced 70 million ounces of gold.
Lexam VG Gold lists on the OTCQX International. The Company is headquartered in Toronto, Ontario. In addition, Lexam has an exploration and operations management office in Timmins, Ontario. Lexam VG Gold formed on January 1, 2011, through the merger of Lexam Explorations, Inc. and VG Gold Corp. This resulted in a company that is 27 percent owned by Chairman Mr. Rob McEwen.
Lexam VG Gold's developed properties hold significant additional potential. This allows for the increase of the resource base. The Company undertakes ongoing exploration programs, targeted to expand gold mineralization, to test the growth potential, as well as to determine the economics on their gold projects.
Major Goldcorp mines surround Lexam VG Gold's assets. The Company's properties include Buffalo Ankerite (100 percent ownership), Fuller (100 percent ownership), Davidson Tisdale (68.50 percent ownership), and Paymaster (60 percent ownership).
The Buffalo Ankerite property is approximately 3.5 miles southeast of Timmins and is part of the prolific Porcupine Gold Camp. Its 1,062 acres of land are easily accessible by highway and are situated approximately two miles east of Goldcorp's Dome Mine. The Fuller Property is in the Tisdale Deloro Townships, approximately 3 km southeast of Timmins, in the heart of the Timmins gold camp. The property is within a radius of 2 kilometers from historic mines that have produced greater than 50 million ounces of gold and that include the Hollinger, McIntyre and Dome Mines. The property neighbors the Buffalo Ankerite Mines to the south and the Paymaster Mine to the east.
Davidson Tisdale is a high-grade gold deposit located in northeastern Timmins, Ontario. The property is a joint venture of which Lexam VG Gold owns 68.5 percent and SGX Resources owns the remainder. Davidson-Tisdale consists of 10 claims totaling 520 acres in the Tisdale Township neighboring the Timmins gold mining camp.
Lexam VG Gold entered into a Joint Venture with Goldcorp on the Paymaster West Property in 2008; in June 2012, the Company earned 60 percent ownership interest. The Paymaster West Property is part of the former producing Paymaster Mine located next to Goldcorp's Dome Mine, which has produced 17 million ounces of gold and is still in operation after 100 years.
Lexam VG Gold, Inc. (LEXVF), closed Tuesday’s session at $0.164, up 4.13%, on 41,600 volume with 2 trades. The average volume for the last 60 days is 46,143 and the stock's 52-week low/high is $0.14/$0.461.
Metanor Resources, Inc. (MTO.V)
AllPennyStocks reported previously on Metanor Resources, Inc. (MTO.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Metanor Resources, Inc. is a gold mining company whose shares trade on the TSX Venture Exchange. The Company focuses on the efficient production, exploration, and development of their properties. Metanor has five gold properties - four in Quebec and one in Ontario - located in the heart of historically prolific mining areas. Metanor Resources is based in Val-d'Or, Quebec.
The properties Bachelor Lake/Hewfran, Barry, and Dubuisson contain a total of approximately 1.6 million ounces of gold (NI 43-101, all categories). Currently, the Bachelor Lake mill is producing gold. It is ramping up to achieve commercial production of 60,000 ounces of gold, using only 800 tons of its 1,200 ton mill capacity.
The Company's Barry Property consists of 408 claims and 1 mining concession. It is 73.49 km2 (7,349 hectares) and 190 km northeast of Val-d'Or, Quebec. Metanor Resources has 100 percent ownership and the property is an open pit operation.
Metanor's Dubuisson Property consists of 14 contiguous unpatented mining claims. It covers 432.11 hectares within the city limits of Val-d'Or, Quebec. Metanor also has their Wahnapitei Property. It is on the southern shore of Lake Wanapitei, approximately 25 km northeast to the Town of Sudbury. The Property consists of two mining leases covering an area of 130 hectares.
In addition, Metanor holds an option enabling the Company to acquire an interest of 70 percent in the Nelligan property. This property includes 58 claims, covering an approximate surface of 2,881 hectares, located immediately at the west of the Bachelor property.
Last month, Metanor Resources released an update regarding the current development of their Bachelor project. They announced on July 6, 2012, that they received their certificate of approval for commercial production. On July 12, 2012, they announced positive results of the bulk sample, 25 percent more gold than expected. With these results, together with that approval, Metanor then proceeded to begin development work to start the ramp up towards commercial production.
During the months of July, August and September 2012, they continued the development in the mineralized 'Main' and 'B' vein structures on levels 12 and 13. They began the development of underground infrastructures including the escape-way, the ore handling system, the permanent dewatering system, and the bulk explosive storage all necessary for eventual commercial production at the Bachelor project. From the end of July to September 30, 2012, the Company produced 3,191 ounces of gold.
Metanor Resources, Inc. (MTO.V), closed Tuesday’s session at $0.26, up 1.96%, on 344,306 volume. The stock's 52-week low/high is $0.20/$0.41.
Mission NewEnergy Ltd. (MNELF)
We are highlighting Mission NewEnergy Ltd. (MNELF), here at the QualityStocks Daily Newsletter.
Incorporated in 2005, Mission NewEnergy Ltd. is a renewable energy company whose shares trade on the OTC Markets: OTC Pink Current Information. The Company is developing a sustainable biofuel feedstock supply and oleochemical company that is enhancing the palm oil value chain and developing a next generation supply of non- food feedstock materials. Mission NewEnergy (formerly known as Mission Biofuels Ltd.) has their headquarters in Subiaco, Western Australia.
The Company has biodiesel refineries in Malaysia; they engage in Jatropha contract farming in India, and they are developing an oleochemical complex in Indonesia. Mission NewEnergy has more than 350,000 tonnes (2.6 million barrels) per annum of biodiesel refining capacity. The Company's refineries are situated at Kuantan Port in Malaysia. Mission NewEnergy has certification for ISO 9001:2008 and is the only biodiesel producer outside of Germany to have met the stringent requirements for the German AGQM (Arbeits Gemeinshaft fuer Qualitaets Management) certification.
Mission is developing their sustainable biofuel feedstock material through contract farming of Jatropha. Jatropha Curcas plants produce inedible oil. The raw oil from the seeds is an ideal input oil "feedstock" for the production of biodiesel, bio-jet fuel or for the production of electricity.
The Company's refineries can produce biodiesel from multiple feedstocks. While Mission's Jatropha supply is building up the Company can use palm oil that is fully certified by the ISCC as sustainable (International Sustainability & Carbon Certification System).
Mission is developing a new downstream palm oil and oleo-chemical complex. They are doing this via a Joint Venture with an Indonesian government owned plantation company. The venture is in North Sumatra. The expectation is that it will consist of a 600,000 tpa edible oil refinery, a toco-trienol extraction facility and a shortening plant. In addition, it will provide for a 250,000 tpa Methyl Ester (biodiesel) plant and a 100,000 tpa Fatty Alcohol plant that will be added in the second stage. The anticipation is that the first stage of the project will be operational by the end of 2014.
Mission NewEnergy Ltd. (MNELF), closed Tuesday’s session at $0.056, down 20.00%, on 1,600 volume with 3 trades. The average volume for the last 60 days is 18,049 and the stock's 52-week low/high is $0.06/$0.35.
Sunvalley Solar, Inc. (SSOL)
FeedBlitz reported earlier on Sunvalley Solar, Inc. (SSOL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Sunvalley Solar, Inc. is a solar power technology and system integration company. They offer complete solar energy technology, system design, installation, equipments, and technical support. The Company offers these for electrical contractors, builders, homeowners, businesses/commercial buildings, and government entities. Sunvalley Solar has their headquarters in Los Angeles, California.
The Company provides an all-in-one service for customers' solar system needs - from system design and permitting, to installation and final inspection. Sunvalley Solar has designed and installed more than two million watts of solar power systems. The Company's experience includes residential, small commercial, and complex large commercial solar system integration projects. The projects include 975kW commercial solar power systems for distribution warehouses and manufacturing companies, and 1MW commercial solar power systems for agriculture farms and cold storage facilities.
Sunvalley Solar is a leading solar electric equipment wholesale distributor for solar photovoltaic equipment of manufacturers including CEEG-SST and Canadian Solar, Inc., in addition to PV Powered and SMA Sunny Boy Inverters. The Company has inventory consisting of over 10MW of solar equipment in stock.
Sunvalley Solar specializes in packaged solar system solutions. Currently, they distribute to more than 600 clients in more than 21 states. They provide solar equipment as well as the aforementioned technical support.
This past August, Blue Earth, Inc. announced that their wholly owned subsidiary, Xnergy, Inc., entered into a joint development agreement with Sunvalley Solar to construct six separate solar projects totaling approximately 1 megawatt of DC in California. The projects are valued at approximately $4.2 million. They consist of six solar PV systems: ground mount and rooftop. Blue Earth is a renewable energy and energy efficiency services company.
In addition, in August, Sunvalley Solar announced that they were awarded a new 112KW solar system installation contract from a food manufacturing company in Santa Ana, California. The 112KW contract is for a system capable of generating 160,338kWh of electrical power each year. The system utilizes 448 pieces of high efficiency 250-Watt Mono-crystalline solar panels. The installation of the project began in September 2012.
Sunvalley Solar, Inc. (SSOL), closed Tuesday’s session at $0.021, up 5.00%, on 110,183 volume with 11 trades. The average volume for the last 60 days is 189,397 and the stock's 52-week low/high is $0.0177/$3.50.
Westinghouse Solar, Inc. (WEST)
Alternative Energy, Greenbackers, Street Insider, OTCPicks, and PennyTrader Publisher reported earlier on Westinghouse Solar, Inc. (WEST), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Westinghouse Solar, Inc. is a designer and manufacturer of integrated rooftop solar power systems. The Company designs and manufactures solar power systems and solar panels with integrated microinverters (which they call AC solar panels). The design of their products is for use in solar power systems for residential and commercial rooftop customers. Westinghouse Solar lists on the OTC Markets: OTCQB. Founded in 2001, the Company has their corporate headquarters in Campbell, California.
Westinghouse Solar designs, markets and sells their solar power systems to solar installers, trade workers and do-it-yourself customers in the United States and Canada via distribution partnerships, the Company's dealer network and retail outlets. The Company introduced their "plug and play" solar panel technology (going by the brand name Andalay), in September 2007.
In 2009, the Company broke new ground with the first integrated AC solar panel, reducing the number of components for a rooftop solar installation by approximately 80 percent and lowering labor costs by approximately 50 percent. This AC panel won the 2009 Popular Mechanics Breakthrough Award. It has become the industry's most widely installed AC solar panel. Westinghouse Solar has just introduced a new generation of products named "Instant Connect".
Westinghouse Solar has three U.S. patents (Patent No. 7,406,800, Patent No. 7,832,157 and Patent No. 7,866,098) that cover key aspects of their solar panel technology, as well as U.S. Trademark No. 3481373 for registration of the mark "Andalay." The Company received three foreign patents in 2010: Australian Patent No. 2,005,248,343, Indian Patent No. 243,626, and Mexican Patent No. 274,182. A Korean Patent No. 751,614 was issued in 2007. At present, the Company has seven issued patents and eighteen other pending U.S. and foreign patent applications that cover the Andalay technology working their way through the USPTO and foreign patent offices.
On May 7, 2012, Westinghouse Solar entered into a Merger Agreement with CBD Energy Ltd. Under the terms of the Merger Agreement, a subsidiary of CBD will be merged with and into the Company, with the Company to be the surviving corporation and a wholly owned subsidiary of CBD.
In September 2012, Westinghouse Solar reported that CBD and the Company anticipate merger closing in January 2013. CBD has applied for listing on the NASDAQ Stock Exchange, to be effective on or before the consummation of the merger. CBD intends to delist from the ASX subject to shareholder approval and upon merger closing.
Westinghouse Solar, Inc. (WEST), closed Tuesday’s session at $0.09, down 10.00%, on 127,308 volume with 25 trades. The average volume for the last 60 days is 67,997 and the stock's 52-week low/high is $0.065/$0.20.
GASFRAC Energy Services, Inc. (GFS.TO)
We are reporting on GASFRAC Energy Services, Inc. (GFS.TO), here at the QualityStocks Daily Newsletter.
GASFRAC Energy Services, Inc. is a well-fracturing company that lists on the Toronto Stock Exchange. The Company has developed a patented waterless Liquid Petroleum Gas (LPG) gel that yields higher reservoir production while eliminating concerns over water use in fracturing. GASFRAC's primary business is to provide LPG fracturing services to oil and gas companies in Canada and the United States. Incorporated in 2006, the Company has their headquarters in Calgary, Alberta.
GASFRAC Energy Services' proven, proprietary Liquid Petroleum Gas (LPG) gel process eliminates the need for water, is safer for employees and allows for better working conditions in the field. The Company's commitment is to provide industry leading stimulation services to maximize customers' well performance while minimizing completion costs.
The LPG used in the closed GASFRAC system is primarily propane, C3H8. This naturally occurring hydrocarbon is non-damaging to the formation. The Company's LPG gel properties include low surface tension, low viscosity, low density, and solubility within naturally occurring reservoir hydrocarbons.
All of these added together create more effective fracture lengths; this enables higher initial and long-term production of the well. An additional advantage is the ability to distribute proppant evenly with their gelled slurry during pumping. This decreases the chance of proppant settling in the formations. GASFRAC's gel can generate a higher pay zone height throughout pumping and subsequent long-term production.
Last week, GASFRAC presented their third quarter 2012 results. Revenue for the quarter decreased 29 percent to $40.9 million from $57.2 million in 2011; revenue in the third quarter of 2011 included a $20.9 million sale of materials to Husky. Adjusting for this sale, revenues from service revenue increased approximately 12 percent in 2012 compared to 2011. Revenue per operating day increased to $448 from $420.
During the quarter, GASFRAC earned revenues from 19 customers with the top three customers accounting for approximately 69 percent of the Company's revenue (2011 – 47 percent). Net loss for the quarter was $7.1 million, compared to a $5.9 million profit during 2011.
GASFRAC Energy Services, Inc. (GFS.TO), closed Tuesday’s session at $1.37, up 0.74%, on 69,965 volume. The stock's 52-week low/high is $1.24/$9.00.
Liberty Star Uranium & Metals Corp. (LBSR)
Xtremepicks, Bird Gang Stocks, PennyTrader Publisher, and Greenbackers reported earlier on Liberty Star Uranium & Metals Corp. (LBSR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Liberty Star Uranium & Metals Corp. is a mineral exploration company with headquarters in Tucson, Arizona. The Company engages in the acquisition and exploration of mineral properties in Arizona and Alaska. They currently control properties totaling approximately 160,000 acres (approximately 250 square miles) located over what their management considers some of North America's richest mineralized regions for uranium, copper, gold, silver and molybdenum (moly).
Liberty Star, by way of their wholly owned subsidiary, Big Chunk Corp., holds claims to the Big Chunk Super Project. This Project covers approximately 177 square miles in southwestern Alaska, targeting copper, gold and molybdenum. The Big Chunk lands are bordering the Pebble property. On July 8, 2010, Liberty Star announced a new partnership with Northern Dynasty Minerals Ltd., holders of the Pebble property. Liberty Star sold 13 percent of their Alaska lands (23.4 square miles) to Northern Dynasty.
Liberty Star's North Pipes Super Project consists of 431 standard Federal lode mining claims covering over 38,000 acres in a number of blocks targeting breccia pipe hosted uranium deposits. Additionally, their Tombstone Super Project initially consisted of 33 unpatented federal lode mining claims over a projected covered porphyry copper mineral center in Cochise County, Arizona. In 2011, more claims were added and three claim zones defined. These are Walnut Creek, Tombstone South and Hay Mountain.
In September, Liberty Star announced that they received word that the application for Arizona State Mineral Exploration Permits (MEPs) within the Tombstone Super Project (TSP) was accepted by the Arizona Department of Mines & Mineral Resources (ADMMR). Furthermore, the Company submitted Drill Permit applications to the ADMMR (July 2012) and received comments back from the ADMMR allowing Liberty Star to go ahead with state mandated archeological reconnaissance over the proposed drill area in the Hay Mountain portion of the TSP.
Liberty Star Uranium & Metals Corp. (LBSR), closed Tuesday’s session at $0.021, down 4.55%, on 375,331 volume with 12 trades. The average volume for the last 60 days is 893,982 and the stock's 52-week low/high is $0.012/$0.0499.
Explore Anywhere Holding Corp. (EAHC)
Atomic Pennies and Insider Wire reported earlier on Explore Anywhere Holding Corp. (EAHC), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Wabash, Indiana, Explore Anywhere Holding Corp. is in the business of selling computer monitoring software and hardware products. They specialize in offering computer monitoring solutions for parents, corporations and educational facilities. Originally founded and incorporated in 2002 as "ExploreAnywhere Software, LLC", the Company has been in the forefront of developing highly advanced computer monitoring and covert surveillance software technologies. Explore Anywhere Holding lists on the OTC Markets: OTCQB.
The Company's dedication is to provide effective and useful computer monitoring products at affordable prices. This is their corporate effort to cut down on the dangers of the Internet and the greater community at large. Their solutions implement technologies designed to address an assortment of emerging online threats. Explore Anywhere Holding works to offer functional, user-friendly software products with innovative features and functionality.
Explore Anywhere Holding offers SpyBuddy 2012. This is the award-winning, powerful Internet spy software and computer monitoring product that allows one to monitor spouses, children, employees, or almost anyone else. SpyBuddy spy software allows one to secretly monitor all areas of their PC. They can track every action down to the last keystroke pressed and the last file deleted. SpyBuddy 2012 monitoring software is virtually undetectable and very user-friendly.
The Company also offers their Keylogger Pro 2012 Remote Keylogger Software. Keylogger Pro silently records keystrokes typed on any keyboard layout (English, Russian, Chinese, Arabic, and more), as well as all passwords, emails, chats and social network activity typed by users of an individual's computer. In addition, Keylogger Pro will take high resolution screen shots (at user's defined speed) of user activity. This allows one to see exactly what the user is seeing. On top of that, Keylogger Pro records all applications/programs used and how long the programs were being used.
Explore Anywhere Holding's software products have been featured in publications such as Fortune Small Business, PC Magazine, Computer User Magazine, and USA Today. They have also been featured on the BBC World News, CNN, Tech TV, and the Kim Komando show.
Explore Anywhere Holding Corp. (EAHC), closed Tuesday’s session at $0.1935, up 1.84%, on 35,296 volume with 20 trades. The average volume for the last 60 days is 118,063 and the stock's 52-week low/high is $0.095/$0.354.
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.70, even for the day, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 816, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. announced significant advancement of their human liver cell-based bioassay system, LiverSafe 3D™, which was engineered to predict liver toxicity and potential drug metabolism issues, all in such a way as it dovetails perfectly with the company's revolutionary drug rescue activities. With 70% albumin-positive human hepatocytes populations now being produced by LiverSafe 3D™, the bioassay platform technology stands to be a real game-changer in the drug development industry via the ability to generate clinically predictive liver toxicology and liver metabolism data at the front end of the drug development process, long before standard animal and human testing.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™
VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.185, off by 3.55%, on 85,596 volume with 96 trades. The stock’s average daily volume over the past 60 days is 207,339, and its 52-week low/high is $0.1771/$0.4605.
Cardium Therapeutics, Inc. announced the showcasing of two poster presentations for their leading topical gel for wound care management product, Excellagen®, at the upcoming Desert Foot 2012 High Risk Diabetic Foot Conference this November 14-16 in Phoenix. President and Medical Director of Associated Foot & Ankle Specialists in Phoenix, Arthur J. Tallis, DPM, as well as Senior Clinical Instructor for the Case Western Reserve University School of Medicine in Cleveland, Howard M. Kimmel, DPM, MBA, FACFAS, will present key case studies in chronic/non-healing category diabetic foot ulcers. Needless to say this will be a superb opportunity to demonstrate the superiority of Excellagen for treating neuropathic and diabetic foot ulcers, as well as generally accelerating the growth of granulation tissue.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
European Union's First Gene Therapy Approval Represents Major Advancement For Industry
FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases
VIASPACE, Inc. (VSPC)
The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.0125, off by 3.85%, on 1,106,318 volume with 24 trades. The stock’s average daily volume over the past 60 days is 1,507,276, and its 52-week low/high is $0.0013/$0.015.
VIASPACE, Inc. reported today that their Giant King™ Grass is now growing in St. Croix, US Virgin Islands as part of a 6MW biomass energy project which draws on a 1k-acre plantation of the breakthrough crop. Sent from the company's grow site in California, this biomass powerhouse was featured by project developer, Tibbar Energy recently in the island's main newspaper with a full-page spread promoting the anaerobic digestion technology to be used, which produces no emissions because the grass isn't being burned, its digested into biogas.
VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.
The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.
VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.
The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer
VIASPACE, Inc. Company Blog
VIASPACE, Inc. News:
Renewable Giant King Grass is Growing in St. Croix; VIASPACE Now on Facebook and Twitter
VIASPACE CEO Presents at Asian Development Bank Renewable Energy Conference and Meets Customers in Myanmar
Board Chairman Interviews With TheStockRadio Program Regarding the Future of VIASPACE
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.18, off by 5.26%, on 171,610 volume with 51 trades. The stock’s average daily volume over the past 60 days is 114,693, and its 52-week low/high is $0.20/$0.69.
International Stem Cell Corp. reported the commercial launch of their newest stem cell based skin care product today, Lifeline® Eye Firming Complex, via wholly-owned subsidiary Lifeline Skin Care, Inc. This next generation anti-aging skincare eye cream will be touted by recently engaged celebrities like Emme, the supermodel and author who was twice-named one of People magazine's 50 Most Beautiful People, and Glamour magazine's Woman of the Year, as well as popular celebrity trainer Jennifer Galardi, a nationally recognized fitness and yoga guru, and the face for fitness brands Adidas, Under Armour, New Balance and Nike. Lifeline Eye Firming Complex complements the current anti-aging product line introduced in November 2010 and available in selected luxury spas, medical offices and online.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch
International Stem Cell Corp Announces Third Quarter 2012 Financial Results
International Stem Cell Corporation to Host Third Quarter 2012 Financial Results Conference Call at 11:00 a.m. ET on Friday, November 9, 2012
VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism screening, today announced a significant advance in its development of LiverSafe 3D™, a human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues in connection with the company’s drug rescue activities.
Shawn K. Singh, VistaGen’s Chief Executive Officer, stated, “As we have done with CardioSafe 3D™, our stem cell-based bioassay system for predictive heart toxicity screening and drug rescue, we are developing LiverSafe 3D™ to change the game in drug development — to generate clinically predictive liver toxicology and liver metabolism data at the front end of the drug development process, long before standard animal and human testing.”
VistaGen’s LiverSafe 3D™, together with optimized culture protocols and without the need for any purification, can now produce differentiated populations of cells containing greater than 70% albumin-positive human hepatocytes (liver cells), and greater than 40% of these hepatocytes express the mature CYP3A4 drug metabolizing enzyme. CYP3A4 is a crucial enzyme in adult liver functions and widely viewed as an important functional marker for adult stem cell-derived hepatocytes. This enzyme is responsible for metabolizing over 50% of the drugs approved by the FDA. With purification, LiverSafe 3D™ can obtain hepatocyte populations approaching 90% expressing the CYP3A4 enzyme.
H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer, commented, “Our LiverSafe 3D™ bioassay system involves custom-designed liver cells that are engineered to indicate when CYP3A4 is produced, and to allow the selection for mature cells expressing CYP3A4. On a per cell basis, LiverSafe 3D™ hepatocytes express functional CYP3A4 drug metabolism activity that approaches 25% to 40% of the metabolic activity seen with some commercial batches of human hepatocytes. We believe that this frequency and activity far exceed most, if not all, comparable data reported in the literature for stem cell-derived human hepatocytes. Our continuing R&D efforts are focused on further improvements of LiverSafe 3D™ to the point where it is comparable in all aspects to commercial human liver cells.”
Primary human cadaveric hepatocytes are well established, and, in many cases, are required by the FDA as an in vitro drug development tool for predicting liver toxicity, drug metabolism, and drug-drug interactions. However, the demand for primary human cadaveric hepatocytes for these studies exceeds the available supply. Even ignoring the supply limitations and high costs, primary human cadaveric hepatocytes have several undesirable attributes for drug development applications, including (1) the health of the donor and quality of the cadaveric hepatocytes received in the laboratory are often not ideal, (2) even high quality cadaveric hepatocytes rapidly lose critical hepatocyte functions important to drug development, and (3) batches of human cadaveric hepatocytes exhibit unknown and uncontrolled genetic variations that can dramatically influence the outcome of drug responses and metabolism. These, and other limitations of primary human cadaveric hepatocytes, highlight a widespread understanding of the pharmaceutical industry’s need for a clinically predictive and readily accessible alternative for drug development. VistaGen is developing LiverSafe 3D™ to meet that need.
For more information on VistaGen and its Human Clinical Trials in a Test Tube™ platform, visit www.vistagen.com
Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced this morning that the company will be displaying two Excellagen® poster presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference being held this week in Phoenix, AZ.
Arthur J. Tallis, DPM, President and Medical Director of Associated Foot & Ankle Specialists in Phoenix, AZ, has been chosen to present the results of three Excellagen case studies, including a venous leg ulcer, neuropathic diabetic foot ulcer, and dehisced surgical wound. In addition, Howard M. Kimmel, DPM, MBA, FACFAS, Senior Clinical Instructor, Case Western Reserve University School of Medicine in Cleveland, OH, will display two case studies involving non-healing diabetic foot ulcers. The majority of the patients’ wounds were classified as chronic and non-healing despite prior treatments, including Dermagraft.
Drs. Tallis and Kimmel’s poster presentations can be viewed at http://www.excellagen.com/meetings-and-publications.html and additional Excellagen case studies are available at http://www.excellagen.com/surgical-wounds.html.
Cardium also reported the publication of the Profiles in Excellence 2012 article, “Excellagen – Advanced Wound Care Made Simple,” in the October issue of Podiatry Management. The article highlights Excellagen’s ease of use, illustrating how easily it fits into existing wound care practices to save physicians time. The product is superior to other treatments that require daily dressing changes and frequent product applications and physician visits. The article can be viewed at http://www.excellagen.com/pdf/ExcellagenProfile1012.pdf.
For more information on Excellagen, visit www.excellagen.com
For more information on Cardium Therapeutics, visit www.cardiumthx.com
For additional information, visit www.CardiumTHX.com
VIASPACE just announced that Giant KingTM Grass is now growing in St. Croix, US Virgin Islands. The initial small shipment of Giant King Grass was sent to Tibbar Energy USVI LLC from VIASPACE’s California location. Tibbar plans to develop a 6 MW biomass energy project fueled by a 1,000 acre Giant King Grass plantation.
Earlier this week, Tibbar Energy placed a full-page advertisement in the main newspaper on the island as part of its public education campaign. The headline in the ad reads “Tibbar Energy USVI Introduces Giant King Grass to St. Croix.”
The text of the ad includes the following:
“How does GKG Help St. Croix?
Tibbar Energy USVI is developing a biomass renewable energy project on St. Croix. The Giant King Grass will be used as a feedstock for anaerobic digestion, generating biogas which will be used to produce electricity. No grass is burned in this process. Anaerobic digestion is a biological process.
The benefits of this project to the island are not only in the energy production. Additional benefits include:
• The branding of St. Croix as a renewable energy producer
• Helping to meet the Virgin Islands renewable energy goal of 22% by 2025
• Provides organic fertilizer for local farmers, agricultural scholarships and new agricultural activity
• Developing co-operative growing agreements with local famers
• Creates high quality permanent jobs.
• Converts 800 acres of underutilized land to agricultural use
• Invests millions of dollars into the island”
Tibbar is an exclusive partnership with VIASPACE to grow Giant King Grass on St. Croix. Slated to be underway in 2013 and fully on-line by Q1 2014, the project is anticipated to generate more than 20 full-time jobs with a total projected economic benefit of $150 million (over the life of the project) to the community through its agricultural and power generation components.
VIASPACE Chairman, Dr. Kevin Schewe, stated, “The VIASPACE project with Tibbar Energy on St. Croix is now moving forward with all due speed as evidenced by this public relations campaign to educate the people of St. Croix regarding the multiple, significant benefits of continuously renewable, green bioenergy using Giant King Grass to produce local electricity. Our partnership with Tibbar Energy on St. Croix will be a model green energy project that can be readily duplicated elsewhere.”
In today’s press release, VIASPACE also announced that the public can connect with the company via Facebook (www.facebook.com/viaspaceinc) and Twitter (www.twitter.com/viaspace). The company aims to bring investors and industry experts together through social media while delivering VIASPACE, renewable energy, and other industry-related news. VIASPACE is eager to reach out to new audiences that are interested in clean, renewable green energy.
For more information on Tibbar Energy, visit www.tibbarenergy.com
For more information on VIASPACE, visit www.viaspace.com
International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, today announced Lifeline Skin Care’s commercial launch of its newest stem cell based skin care product.
The new Lifeline® Eye Firming Complex is now available to shareholders, followers, and supporters of ISCO and Lifeline Skin Care. On Thursday the product will be available online (www.lifelineskincare.com), in selected spas, and medical clinics.
“This addition to our skincare line has been highly anticipated,” says Donna Queen, President of Lifeline Skin Care. “An eye treatment was the #1 request by our customers.”
Lifeline Eye Firming Complex complements the current anti-aging product line introduced in November 2010 and available in selected luxury spas, medical offices, and online. The extended Lifeline product line will be promoted by recently engaged celebrities including Emme, the supermodel and author who was twice-named one of People magazine’s 50 Most Beautiful People, and Glamour magazine’s Woman of the Year; and Jennifer Galardi, a celebrity trainer, nationally recognized fitness and yoga guru, and the face for fitness brands Adidas, Under Armour, New Balance, and Nike.
According to supermodel and beauty expert Emme, “Women are concerned about their appearance, and they’re especially concerned about the lines and wrinkles around their eyes. That’s why they’ll like Lifeline’s new eye cream — women want something that really works.”
Considered a “must-have” in anti-aging skincare, eye creams are typically the most popular product with customers. The new Eye Firming Complex includes novel ingredients designed to produce beneficial results, including peptides and HSC-X™ — the human stem cell extract developed and patented by International Stem Cell Corporation which is used in the company’s anti-aging Day and Night serums.
For more information, visit www.internationalstemcell.com
Today's Top 3
The Howard Group
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
- GreeneStone Healthcare Corp. (GRST) Seeks Amex Listing - New Report Confirms Demand
- International Stem Cell Corp. (ISCO) Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for the Third Quarter of 2012
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- TNI BioTech Inc. (TNIB) and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
- VistaGen Therapeutics, Inc. (VSTA) Completes $3.25 Million Financing and $3.0 Million Debt Restructuring